{"denoms":[{"counts":[{"groupId":"BG000","value":"102"}],"units":"Participants"}],"groups":[{"description":"Regimen was 14 mg/m2 IV over a 4-hour period on Days 1, 8, and 15 of a 28-day cycle. The protocol included 6 cycles of treatment; responding patients and patients who achieved at least Stable Disease (SD) had the option of continuing treatment beyond 6 cycles at the discretion of the Investigator and based on local regulations.","id":"BG000","title":"Romidepsin"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}],"title":"<=18 years"},{"measurements":[{"groupId":"BG000","value":"79"}],"title":"Between 18 and 65 years"},{"measurements":[{"groupId":"BG000","value":"23"}],"title":">=65 years"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Age, Categorical","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"11.93","value":"57.0"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"40"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"62"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"5"}]}],"title":"France"},{"categories":[{"measurements":[{"groupId":"BG000","value":"20"}]}],"title":"United States"},{"categories":[{"measurements":[{"groupId":"BG000","value":"24"}]}],"title":"Poland"},{"categories":[{"measurements":[{"groupId":"BG000","value":"17"}]}],"title":"Russian Federation"},{"categories":[{"measurements":[{"groupId":"BG000","value":"6"}]}],"title":"Germany"},{"categories":[{"measurements":[{"groupId":"BG000","value":"20"}]}],"title":"United Kingdom"},{"categories":[{"measurements":[{"groupId":"BG000","value":"3"}]}],"title":"Georgia"},{"categories":[{"measurements":[{"groupId":"BG000","value":"7"}]}],"title":"Ukraine"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"53"}]}],"title":"0, Fully active, able to carry on all pre-disease"},{"categories":[{"measurements":[{"groupId":"BG000","value":"49"}]}],"title":"1, Restricted in physically strenuous activity but"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}]}],"title":"2, Ambulatory and capable of all selfcare but unab"}],"paramType":"NUMBER","title":"Eastern Cooperative Oncology Group (ECOG) Performance status","unitOfMeasure":"Participants"}]}